Literature DB >> 17420210

In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea.

Jong Hwa Yum1, Chang Ki Kim, Dongeun Yong, Kyungwon Lee, Yunsop Chong, Cheol Min Kim, Jeong Mi Kim, Seonggu Ro, Joong Myung Cho.   

Abstract

The in vitro activities of CG400549, a novel FabI inhibitor, were compared to those of linezolid and commonly used antimicrobials against recent bacterial isolates. CG400549 had an MIC(90) of 0.5 microg/ml for Staphylococcus aureus strains and was more potent than either linezolid or vancomycin.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17420210      PMCID： PMC1913239          DOI： 10.1128/AAC.01562-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  Korean Nationwide Surveillance of Antimicrobial Resistance of Bacteria in 1998.

Authors:  K Lee; C L Chang; N Y Lee; H S Kim; K S Hong; H C Cho
Journal:  Yonsei Med J       Date:  2000-08       Impact factor: 2.759

2.  Structure of acyl carrier protein bound to FabI, the FASII enoyl reductase from Escherichia coli.

Authors:  Salma Rafi; Polina Novichenok; Subramaniapillai Kolappan; Christopher F Stratton; Richa Rawat; Caroline Kisker; Carlos Simmerling; Peter J Tonge
Journal:  J Biol Chem       Date:  2006-09-29       Impact factor: 5.157

3.  16S rRNA gene-based detection of tetrachloroethene-dechlorinating Desulfuromonas and Dehalococcoides species.

Authors:  F E Löffler; Q Sun; J Li; J M Tiedje
Journal:  Appl Environ Microbiol       Date:  2000-04       Impact factor: 4.792

Review 4.  Oxazolidinone antibiotics.

Authors:  D J Diekema; R N Jones
Journal:  Lancet       Date:  2001-12-08       Impact factor: 79.321

5.  4-Pyridone derivatives as new inhibitors of bacterial enoyl-ACP reductase FabI.

Authors:  Hideo Kitagawa; Ko Kumura; Sho Takahata; Maiko Iida; Kunio Atsumi
Journal:  Bioorg Med Chem       Date:  2006-10-13       Impact factor: 3.641

6.  Discovery of a novel and potent class of FabI-directed antibacterial agents.

Authors:  David J Payne; William H Miller; Valerie Berry; John Brosky; Walter J Burgess; Emile Chen; Walter E DeWolf; Andrew P Fosberry; Rebecca Greenwood; Martha S Head; Dirk A Heerding; Cheryl A Janson; Deborah D Jaworski; Paul M Keller; Peter J Manley; Terrance D Moore; Kenneth A Newlander; Stewart Pearson; Brian J Polizzi; Xiayang Qiu; Stephen F Rittenhouse; Courtney Slater-Radosti; Kevin L Salyers; Mark A Seefeld; Martin G Smyth; Dennis T Takata; Irene N Uzinskas; Kalindi Vaidya; Nicola G Wallis; Scott B Winram; Catherine C K Yuan; William F Huffman
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

Review 7.  Linezolid in vitro: mechanism and antibacterial spectrum.

Authors:  David M Livermore
Journal:  J Antimicrob Chemother       Date:  2003-05       Impact factor: 5.790
  7 in total
  16 in total

1.  A Pathogen-Selective Antibiotic Minimizes Disturbance to the Microbiome.

Authors:  Jiangwei Yao; Robert A Carter; Grégoire Vuagniaux; Maryse Barbier; Jason W Rosch; Charles O Rock
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

2.  Recent Advances in the Rational Design and Optimization of Antibacterial Agents.

Authors:  Jesse A Jones; Kristopher G Virga; Giuseppe Gumina; Kirk E Hevener
Journal:  Medchemcomm       Date:  2016-07-07       Impact factor: 3.597

3.  Structure of the Yersinia pestis FabV enoyl-ACP reductase and its interaction with two 2-pyridone inhibitors.

Authors:  Maria W Hirschbeck; Jochen Kuper; Hao Lu; Nina Liu; Carla Neckles; Sonam Shah; Steffen Wagner; Christoph A Sotriffer; Peter J Tonge; Caroline Kisker
Journal:  Structure       Date:  2012-01-11       Impact factor: 5.006

Review 4.  Structural approaches to pathway-specific antimicrobial agents.

Authors:  Michael E Johnson; Leslie W-M Fung
Journal:  Transl Res       Date:  2020-02-06       Impact factor: 7.012

5.  Rational questing for potential novel inhibitors of FabK from Streptococcus pneumoniae by combining FMO calculation, CoMFA 3D-QSAR modeling and virtual screening.

Authors:  Qingye Zhang; Chan Yu; Jun Min; Yan Wang; Jin He; Ziniu Yu
Journal:  J Mol Model       Date:  2010-09-23       Impact factor: 1.810

Review 6.  Bacterial fatty acid metabolism in modern antibiotic discovery.

Authors:  Jiangwei Yao; Charles O Rock
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2016-09-23       Impact factor: 4.698

7.  Epoxy Isonitriles, A Unique Class of Antibiotics: Synthesis of Their Metabolites and Biological Investigations.

Authors:  Guillaume Ernouf; Ingrid K Wilt; Sara Zahim; William M Wuest
Journal:  Chembiochem       Date:  2018-10-31       Impact factor: 3.164

8.  Selectivity of Pyridone- and Diphenyl Ether-Based Inhibitors for the Yersinia pestis FabV Enoyl-ACP Reductase.

Authors:  Carla Neckles; Annica Pschibul; Cheng-Tsung Lai; Maria Hirschbeck; Jochen Kuper; Shabnam Davoodi; Junjie Zou; Nina Liu; Pan Pan; Sonam Shah; Fereidoon Daryaee; Gopal R Bommineni; Cristina Lai; Carlos Simmerling; Caroline Kisker; Peter J Tonge
Journal:  Biochemistry       Date:  2016-05-17       Impact factor: 3.162

9.  Essentiality of FASII pathway for Staphylococcus aureus.

Authors:  Wendy Balemans; Nacer Lounis; Ron Gilissen; Jerome Guillemont; Kenny Simmen; Koen Andries; Anil Koul
Journal:  Nature       Date:  2010-01-21       Impact factor: 49.962

10.  In vitro activities of panduratin A against clinical Staphylococcus strains.

Authors:  Yaya Rukayadi; Kwanghyung Lee; Sunghwa Han; Dongeun Yong; Jae-Kwan Hwang
Journal:  Antimicrob Agents Chemother       Date:  2009-08-03       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.